Diko : en:injection, factor viii fc fusion protein(recombinant), per iu

en:injection, factor viii fc fusion protein(recombinant), per iu

Catégories

Nom

Informations lexicales

Langue:anglais

Informations sémantiques

source:wiki

Liens externes

›

umls:C4067607

Associations d'idées

[F]

›

219

en:5% dextrose/normal saline (500 ml = 1 unit) administered

•

en:5% dextrose/water (500 ml = 1 unit) administered

•

en:abdominal aortic aneurysm is not infarenal

•

en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient

•

en:aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)

•

en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed

•

en:anti-inhibitor, per i.u.

•

en:anti-lipid treatment at discharge

•

en:anticoagulation not ordered for reasons documented by clinician

•

en:antiplatelet medication contraindicated

•

en:antithrombin iii (human), per i.u. administered

•

en:assessed level of activity and symptoms

•

en:autologous cultured chondrocytes, implant

•

en:beta-blocker at discharge

•

en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression

•

en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation)

•

en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique

•

en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer

•

en:complete gene sequence analysis; mlh1 gene

•

en:compounded drug, not otherwise classified

•

en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month

•

en:contraceptive supply, hormone containing vaginal ring, each

•

en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet

•

en:counseling for diet and physical activity not performed, reason not given

•

en:counseling for diet and physical activity performed

•

en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:diabetes screening test not performed, reason not given

•

en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes

•

en:documentation of diagnosis of chronic kidney disease

•

en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)

•

en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)

•

en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)

•

en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)

•

en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter

•

en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter

•

en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record

•

en:electronic wrist rotator, otto bock or equal

•

en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy

•

en:etonogestrel (contraceptive) implant system, including implant and supplies

•

en:factor ix (antihemophilic factor, purified, non-recombinant) per i.u.

•

en:factor ix (antihemophilic factor, recombinant) per i.u.

•

en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u.

•

en:factor viia (antihemophilic factor, recombinant), per 1 microgram administered

•

en:factor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified

•

en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.

•

en:fluocinolone acetonide, intravitreal implant

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed

•

en:follow-up cta, duplex, or mra of the abdomen and pelvis performed

•

en:ganciclovir, 4.5 mg, long-acting implant

•

en:genetic testing for canavan disease

•

en:genetic testing for gaucher disease

•

en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes

•

en:grafix prime, per square centimeter

•

en:hcpcs level ii preferred terms, obsolete

•

en:hyaluronan or derivative, euflexxa, for intra-articular injection, per dose

•

en:hyaluronan or derivative, gel-one, for intra-articular injection, per dose

•

en:hyaluronan or derivative, gel-syn, for intra-articular injection, 0.1 mg

•

en:hyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose

•

en:hyaluronan or derivative, monovisc, for intra-articular injection, per dose

•

en:hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg

•

en:i intend to report the back pain measures group

•

en:i intend to report the community-acquired pneumonia (cap) measures group

•

en:i intend to report the epilepsy measures group

•

en:i intend to report the hypertension (htn) measures group

•

en:i intend to report the perioperative care measures group

•

en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain

•

en:implanted pleural catheter, each

•

en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit

•

en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)

•

en:infusion, normal saline solution, sterile (500 ml=1 unit)

•

en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)

•

en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270)

•

en:injection, alemtuzumab, 10 mg administered

•

en:injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u.

•

en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.)

•

en:injection, belinostat, 10 mg

•

en:injection, brentuximab vedotin, 1 mg

•

en:injection, dexamethasone, intravitreal implant, 0.1 mg

•

en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg

•

en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered

•

en:injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu

•

en:injection, factor ix, fc fusion protein (recombinant), per iu

•

en:injection, factor viii, fc fusion protein, (recombinant), per i.u.

•

en:injection, factor xiii a-subunit, (recombinant), per iu

•

en:injection, ferric carboxymaltose, 1 mg

•

en:injection, fluocinolone acetonide, intravitreal implant, 0.01 mg

•

en:injection, human fibrinogen concentrate, 100 mg

•

en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg

•

en:injection, medroxyprogesterone acetate, 50 mg

•

en:injection, morphine sulfate, 100mg

•

en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg

•

en:injection, ocriplasmin, 0.125 mg

•

en:injection, peginesatide, 0.1 mg (for esrd on dialysis)

•

en:injection, pertuzumab, 10 mg

•

en:injection, sculptra, 0.1 ml

•

en:injection, sulfur hexafluoride lipid microsphere, per ml

•

en:injection, taliglucerase alfa, 10 units

•

en:injection, testosterone cypionate, up to 100 mg

•

en:injection, testosterone enanthate, up to 100 mg administered

•

en:injection, testosterone enanthate, up to 200 mg administered

•

en:injection, von willebrand factor complex (human), wilate, 1 i.u. vwf:rco

•

en:injection, von willebrand factor complex (humate-p), per iu vwf:rco

•

en:injection, ziv-aflibercept, 1 mg

•

en:injection, zoledronic acid (zometa), 1 mg administered

•

en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)

•

en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed

•

en:ldl value >= 100

•

en:ldl-c not performed, reason not given

•

en:ldl-c was not performed

•

en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given

•

en:level of activity and symptoms not assessed

•

en:levonorgestrel (contraceptive) implant system, including implants and supplies

•

en:levonorgestrel 52mg intrauterine system

•

en:levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5 year duration

•

en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:lipid profile not performed, reason not given

•

en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)

•

en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason

•

en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a

•

en:methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram

•

en:miscellaneous supply or accessory for use with ventricular assist device

•

en:mitomycin, ophthalmic, 0.2 mg

•

en:most recent blood pressure under control

•

en:most recent ldl-c not under control, results documented and reviewed

•

en:most recent ldl-c under control, results documented and reviewed

•

en:most recent office visit diastolic blood pressure, 80 - 89 mm hg

•

en:most recent systolic blood pressure >= 140 mm hg

•

en:netupitant 300 mg and palonosetron 0.5 mg

•

en:no anti-lipid treatment at discharge

•

en:no documentation of disease type, anatomic location, and activity, reason not given

•

en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score

•

en:oral aspirin or other antithrombotic therapy prescribed

•

en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given

•

en:patch closure used for patient undergoing conventional cea

•

en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit

•

en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery

•

en:patient documentation - angina assessed as absent

•

en:patient documentation - angina assessed as present

•

en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb)

•

en:patient had a medical visit in the last 6 months

•

en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility

•

en:patient not treated for attention disorder

•

en:patient not treated for memory disorder

•

en:patient not treated for motor speech disorder

•

en:patient not treated for reading disorder

•

en:patient not treated for spoken language expression disorder

•

en:patient receiving antiviral treatment for hepatitis c documented

•

en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge

•

en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge

•

en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge

•

en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase

•

en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase

•

en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days

•

en:patients with a positive hepatitis c antibody test

•

en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given

•

en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine

•

en:pneumocystis jiroveci pneumonia prophlaxis prescribed

•

en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches

•

en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents

•

en:positive airway pressure therapy not prescribed

•

en:prednisone, oral, per 5 mg

•

en:pregnancy test (urine or serum) not ordered for reasons documented by clinician

•

en:pregnancy test (urine or serum) was not ordered, reason not specified

•

en:prescription(s) generated and transmitted via a qualified erx system

•

en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

•

en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given

•

en:prostate cancer antigen 3 (pca3) testing

•

en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge

•

en:rehabilitation services were not ordered, reason not otherwise specified

•

en:ringers lactate infusion, up to 1000 cc

•

en:score on the attention functional communication measure at discharge was higher than at admission

•

en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given

•

en:score on the motor speech functional communication measure at discharge was higher than at admission

•

en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given

•

en:score on the reading functional communication measure at discharge was higher than at admission

•

en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given

•

en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission

•

en:score on the spoken language expression functional communication measure at discharge was higher than at admission

•

en:score on the swallowing functional communication measure at discharge was higher than at admission

•

en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given

•

en:score on the writing functional communication measure at discharge was higher than at admission

•

en:serum creatinine test not performed, reason not given

•

en:severity of angina assessed according to level of activity

•

en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer

•

en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap

•

en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])

•

en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given

•

en:suicide risk assessed at the initial evaluation

•

en:suicide risk not assessed at the initial evaluation, reason not given

•

en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens

•

en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea

•

en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries

•

en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act

•

en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals

•

en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v])

•

en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device

•

en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel

•

en:unlisted procedure, intestine

•

en:urine protein test was not performed, reason not given

•

en:vacuum drainage bottle and tubing for use with implanted catheter

•

en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission

•

en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)

•

en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask)

•

injection ▷

•

protéine

◀

‹

218